# A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

> **NCT02915159** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 250 (actual)

## Conditions studied

- Sjogrens Disease

## Interventions

- **BIOLOGICAL:** Abatacept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02915159
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-06
- **Primary completion:** 2018-08-07
- **Final completion:** 2019-07-23
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02915159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02915159, "A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02915159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*